权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Prognostic Markers of Emphysema Progression

肺气肿进展的预后标志物

基本信息

批准号：
10368048
负责人：
Raul San Jose Estepar
金额：
$ 68.8万
依托单位：
BRIGHAM AND WOMEN'S HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-03-15 至 2024-02-29
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10368048
关键词：
Address Affect Alveolar wall Appearance Architecture Biological Markers Cause of Death Characteristics Chest Chronic Chronic Bronchitis Chronic Obstructive Pulmonary Disease Clinical Clinical stratification Complement Connective Tissue Data Deposition Development Disease Disease Progression Distal Fracture Genetic Goals Histologic Image Impairment Inflammation Inflammation Process Inflammatory Injury Investigation Joints Lead Logistic Regressions Lung Lung volume reduction surgery Machine Learning Maps Measurement Mechanical Stress Mechanics Mediating Medical Genetics Methodology Modeling Outcome Pathologic Processes Pathway interactions Patient risk Patients Pattern Persons Plasma Predisposition Process Prognostic Marker Property Pulmonary Emphysema Radiology Specialty Regression Analysis Reporting Reproducibility Research Risk Scanning Smoker Staging Structure of parenchyma of lung Supervision Techniques Therapeutic Tissues Translating Translations United States Validation X-Ray Computed Tomography base clinical application clinical phenotype clinical practice cohort convolutional neural network cost deep learning density experience expiration follow-up functional decline genetic association improved in vivo inclusion criteria inflammatory marker insight inspiration expiration mechanical properties novel novel therapeutics patient stratification preservation prognostic prognostic model prognostic value prognostication progression marker prospective pulmonary function reduce symptoms respiratory response response to injury risk stratification specific biomarkers tissue stress tobacco smoke exposure

项目摘要

Project Summary/Abstract Chronic Obstructive Pulmonary Disease (COPD) affects up to 24 million people in the United States and is projected to be the 3rd leading cause of death worldwide by 2020 with a total cost of $50 billion. COPD has been traditionally dichotomized into the clinical phenotypes of emphysema and chronic bronchitis, but its underlying mechanisms are poorly understood. In particular, emphysema is defined as abnormal, permanent dilation of the distal airspaces. The development and progression of this pathologic process are associated with a decline in lung function and progressive clinical impairment. Computed tomographic (CT) imaging of the chest is increasingly being leveraged to quantify the disease and its progression objectively. Current approaches to quantify emphysema progression are limited and discard most of the spatial and temporal information in CT scans obtained at inspiration and expiration. In this proposal, we plan on developing computational components to prognosticate emphysema progression that builds upon image density markers and lung mechanical strain characteristics conditioned on their underlying emphysema subtypes. This proposal leverages our previous experience in computational emphysema subtyping to discover, validate and translate a novel panel of prognostic markers tailored around the postulated mechanisms of emphysema progression: inflammation injury and mechanical strain. To reach this goals, we will (1) develop an advanced emphysema subtyping approach using novel deep learning architectures, (2) develop a fast mass preserving large displacement registration approach to enable the discovery of local elastic properties of lung tissue between inspiratory and expiration CT scans, (3) discover new subtype-specific biomarker features based on image density relations and mechanical properties using unsupervised deep learning techniques within a common statistical framework, and (4) validate the prognostic value of the proposed biomarkers and their association with decline end-points and clinical outcomes to enable its clinical interpretation and translation. In addition to that, will be explored alternative prognostic models based on advanced machine learning techniques and performed a model comparison study to define the most prognostic model for emphysema progression. Our analysis will process 12,300 scans corresponding to 5,517 subjects with baseline and follow-up data from the COPDGene cohort –one of the largest cohort in COPD containing CT images at inspiration and expiration, respiratory and genetic measurements. The proposed methodology will provide reproducible, automatic and low-cost prognostic in-vivo biomarkers of emphysema progression that may enable the discovery of new therapies and translate them into clinical practice.

项目总结/文摘